Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ITIL-306 |
Synonyms | |
Therapy Description |
ITIL-306 comprises autologous tumor infiltrating lymphocytes, which potentially induce antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ITIL-306 | ITIL 306|ITIL306|Autologous CoStAR-TILs ITIL-306 | ITIL-306 comprises autologous tumor infiltrating lymphocytes engineered to express a costimulatory antigen receptor targeting FOLR1 as well as the CD28 and CD40 costimulatory domains, which potentially induce killing of FOLR1-expressing tumor cells and enhance antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05397093 | Phase I | ITIL-306 | ITIL-306 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |